拉米夫定和阿德福韦酯联合治疗乙型肝炎肝硬化患者疗效分析

doi:10.3969/j.issn.1672-5069.2017.03.029

Abstract

ZhangYiqiang, Shi Fugui. Efficacy of combination of lamivudine and adefovir dipivoxil in treatment of patients with hepatitis B cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 360-361.

[1] 王晓霞,邹正升,李保森,等. 2002至2011年中国“北方”地区住院肝硬化患者病因构成及变化趋势分析. 实用肝脏病杂志,2014,17(2):154-158.
[2] 曹忆嵘,彭利军,欧阳阳阳,等. 乙型肝炎病毒感染患者肝硬化发生相关临床危险因素评价. 肝脏,2013,18(4):211-215.
[3] Moreau R,Jalan R,Gines P,et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology,2013,144(7):1-9.
[4] Tanaka M,Suzuki F,Seko Y,et al.Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol,2013,49(3):105-108.
[5] 李剑鸿. 肝硬化患者凝血功能变化与其肝功能分级的关系研究. 现代中西医结合杂志,2012,21(4):425-426.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[7] 王世鑫. 肝硬化的诊断标准和治疗方案. 中国临床医生, 2000,8(10):25-26.
[8] 奚蕾,沈伟生,杨洪志,等. 益胃汤加味治疗肝硬化并发原发性肝癌凝血功能紊乱. 现代中西医结合杂志,2012,21(6):576-577.
[9] 王卓强,徐震,王恒林. 失代偿期肝硬化和急性肝衰竭患者肝移植术中的凝血功能比较与调控. 中国急救医学,2013,33(9):821-825.
[10] Michael T,Wolfgang M,Umer C,et al.Differential kinetics of coagulation factors and natural anticoagulants in patients with liver cirrhosis:Potential clinical implications. Plos One,2016,11(5):e0155337-e0155341.
[11] 林壮琼,张展青. 肝硬化患者凝血功能和血小板检测分析. 检验医学与临床,2013,10(8):986-987.
[12] 占国清,谭华炳,李儒贵,等. 血清前白蛋白、总胆汁酸、凝血指标、血小板参数检测在肝硬化中的临床意义. 中国肝脏病杂志电子版,2014,4(1):59-62.
[13] Youngwon N,Kim J E,Lim H S,et al.Coagulation proteins influencing global coagulation assays in cirrhosis:hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. Biomed Res Int,2013,2013(1):217-222.
[14] 马伟. 肝硬化患者凝血3项和抗凝血酶Ⅲ检测分析. 检验医学与临床,2012,9(6):708-709.
[15] 黄英男,吴昊,沈锡中. 乙型肝炎肝硬化抗病毒治疗研究进展. 世界临床药物,2012,33(9):233-238.
[16] 马萍,薛燕,王磊,等. 长期抗病毒治疗对失代偿期乙型肝炎肝硬化患者预后的影响. 山东医药,2012,52(13):22-24.
[17] Montagnani M,Giandinoto M,Lisotti A,et al.High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci,2012,57(2):561-567.
[18] Honda K,Seike M,Maehara S I,et al.Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis. World J Gastroenterol,2012,18(20):2586-2590.
[19] 陈亚芳. 拉米夫定和阿德福韦酯初始联合抗病毒治疗乙型肝炎肝硬化失代偿期临床研究. 现代中西医结合杂志,2014,23(32):3586-3588.
[20] Gigi E,Sykia A,Sinakos E,et al.Virologic response and resistance to lamivudine in patients with chronic hepatitis B:a ten-year retrospective analysis. Hippokratia,2012,16(4):342-346.
[21] 陈立章,薛静,刘立亚,等. 血清HBV-DNA定量检测与凝血指标对乙型肝炎患者病情诊断的研究. 中国现代医学杂志,2013,23(30):31-36.

Efficacy of combination of lamivudine and adefovir dipivoxil in treatment of patients with hepatitis B cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[7]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[11]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[12]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[13]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[14]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[15]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.